Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

Novo Nordisk (NVO) and Viking Therapeutics (VKTX), prominent GLP-1 market participants, both face significant investment risks and hold bearish ratings. Novo Nordisk, the market leader, is contending with slowing uptake of Wegovy and Ozempic due to compounded alternatives and strong competition from Eli Lilly, resulting in a recent guidance cut and leadership transition. Clinical-stage Viking Therapeutics, while showing promise with its VK2735 candidate, experienced investor concern following mixed mid-stage oral study results that highlighted tolerability issues. Despite these setbacks, VKTX's robust cash position and lower valuation position it as a comparatively safer medium-term bet than NVO, which faces more entrenched structural challenges, though Eli Lilly is ultimately suggested as the more prudent long-term obesity market investment.

Analysis

Both Novo Nordisk and Viking Therapeutics are facing significant execution risks within the competitive GLP-1 obesity market, reflected in their symmetric year-to-date stock declines of approximately 35% and bearish analyst ratings. Novo Nordisk, despite its market leadership with a 51.9% value share, is contending with slowing momentum for its key drugs, Wegovy and Ozempic, due to competition from illegal compounded versions and significant market share erosion from Eli Lilly, whose competing drugs generated $14.7 billion in H1 2025. This pressure is underscored by NVO's recent guidance cut, downward-trending earnings estimates, and a CEO transition amidst market headwinds. Furthermore, its pipeline follow-up, CagriSema, delivered less weight loss than expected in late-stage trials. In contrast, Viking Therapeutics is a clinical-stage entity whose primary risk is developmental. Its lead oral candidate, VK2735, demonstrated strong efficacy with 12.2% weight loss, but this was overshadowed by significant patient dropouts, raising critical questions about tolerability, safety, and the company's viability as an acquisition target. While VKTX lacks a marketed product and its next major data readout is not until late 2026, it holds a strong financial position with $808 million in cash, zero debt, and a more compelling valuation with a price-to-book ratio of 3.68 versus NVO's 9.67.

Key Decisions for Investors

• Investors should exercise caution with Novo Nordisk, as its recent guidance cut, leadership transition, and intense competition from Eli Lilly signal significant structural headwinds that could impede a near-term recovery.
• Consider Viking Therapeutics only as a high-risk, speculative position, where the investment thesis is contingent on the company resolving the tolerability and safety concerns for its lead candidate, VK2735, though its strong balance sheet provides a partial buffer.
• For investors seeking long-term, more stable exposure to the obesity market, Eli Lilly may represent a more prudent alternative, given its strong sales momentum, raised corporate guidance, and competitive dominance highlighted in the report.
• Monitor key upcoming catalysts, including the FDA's year-end decision on oral Wegovy for NVO and any updates from VKTX on mitigating the side effects of oral VK2735, as these events will be critical in shaping the investment outlook for both companies.